Mark Eisner - 21 Feb 2023 Form 4 Insider Report for FIBROGEN INC (FGEN)

Reporting relationship: Chief Medical Officer
Issuer ticker: FGEN
Reported as of: 21 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2023, 19:38:25 UTC
Prior SEC filing: 02 Dec 2022
Next SEC filing: 06 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Cecelia Monoarfa-Taime, Attorney-in-fact

Key filing fact

Mark Eisner filed Form 4 for FIBROGEN INC (FGEN) on 23 Feb 2023.

Key facts

This page summarizes Mark Eisner's Form 4 filing for FIBROGEN INC (FGEN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2023, 19:38.

Change

Previous filing in this sequence was filed on 02 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FGEN transaction

Common Stock

Award

Transaction value: $0
Shares: +32,500
Change %: +23%
Price: $0.000000
Shares after: 173,683
Date: 21 Feb 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FGEN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +55,000
Change %
Price: $0.000000
Shares after: 55,000
Date: 21 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $22.60
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2024, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years.

Footnote F2

Twenty-five percent of the shares subject to the option will vest on March 1, 2024, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years.